Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
MMP3	4314	CHEMBL358064	CHEMBL358064		DrugBank	17139284, 17016423
MMP3	4314	CHEMBL1234479	CHEMBL1234479		DrugBank	17139284, 17016423
MMP3	4314	CHEMBL38851	CHEMBL38851		DrugBank	10592235
MMP3	4314	CHEMBL311932	CHEMBL311932		DrugBank	10592235
MMP3	4314	CHEMBL176602	CHEMBL176602		DrugBank	10592235
MMP3	4314	CGS-27023A	CHEMBL514138	inhibitor	GuideToPharmacologyInteractions
MMP3	4314	PRINOMASTAT	CHEMBL75094	vaccine	TALC
MMP3	4314	CHEMBL1234370	CHEMBL1234370		DrugBank	17139284, 17016423, 10592235
MMP3	4314	CHEMBL1233772	CHEMBL1233772		DrugBank	10592235
MMP3	4314	MARIMASTAT	CHEMBL279785	antagonist	TdgClinicalTrial, TEND, DrugBank	11752352
MMP3	4314	CHEMBL176467	CHEMBL176467		DrugBank	17139284, 17016423, 10592235
MMP3	4314	CHEMBL7390	CHEMBL7390		DrugBank	17139284, 17016423, 10592235
MMP3	4314	CHEMBL117225	CHEMBL117225	inhibitor	GuideToPharmacologyInteractions
MMP3	4314	3-METHYLPYRIDINE	CHEMBL15722		DrugBank	17139284, 17016423
MMP3	4314	CHEMBL249847	CHEMBL249847		DrugBank	10592235
MMP3	4314	CHEMBL290140	CHEMBL290140		DrugBank	10592235
MMP3	4314	ILOMASTAT	CHEMBL19611	inhibitor	TTD

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
MMP3	rs35068180	A/del + AA	pravastatin	efficacy	yes	Benefit from pravastatin treatment was only seen in those with the A/del (6A/5A) or AA (6A/6A) genotype and not in patients with the del/del genotype (5A/5A). In the placebo group, patients with the A/del (6A/5A) or AA (6A/6A) genotype had almost 2x the frequency of clinical events in the 2 year follow-up (26.4% and 25.8%, respectively), compared to patients with the del/del genotype (5A/5A 12.1%), which was reduced almost by half in the pravastatin treatment group in those with the A/del (9.4%) and AA (13.8%) genotypes but not 5A/5A (17%).	Genotypes A/del + AA are associated with increased response to pravastatin in men with Coronary Artery Disease.	10190398	1450043998